Image patients with Ga 68 dotatate PET just prior to dosing with long-acting somatostatin analogs. Somatostatin analogs competitively bind to the same somatostatin receptors as Ga 68 dotatate and may affect imaging. Updated June 2, 2016.Lanreotide decreases effects of gallium Ga 68 dotatate by receptor binding competition.

FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. Netspot is marketed by Advanced Accelerator Applications USA, Inc. The FDA granted Priority Review and orphan drug designations for Netspot Priority review status is granted to applications for drugs that, if approved, would be a significant improvement in safety or effectiveness in the treatment of a serious condition. Orphan drug designation provides incentives such as tax credits, user fee waivers, and eligibility for orphan drug exclusivity to assist and encourage the development of drugs for rare diseases. No serious adverse reactions have been identified.

Netspot contributes to overall long-term cumulative radiation exposure, and patients should drink and urinate as often as possible during the first hours following administration to help reduce this risk.

The results of all three studies confirmed the usefulness of Ga 68 dotatate images in finding the location of the neuroendocrine tumors. The first compared Ga 68 dotatate images of NETs to images obtained with an approved drug, and then confirmed with computed tomography (CT) and/ or magnetic resonance imaging (MRI) the second evaluated Ga 68 dotatate images using histopathology (the study of tissue changes caused by disease), or clinical follow up as reference standards and the third evaluated patients with NET recurrence using Ga 68 dotatate images. Three studies established the safety and effectiveness of Netspot. The uptake of Ga 68 dotatate may need to be confirmed by histopathology or other assessments. This uptake can also be seen in a variety of other tumor types or other pathologic conditions, or might occur as a normal variant. The uptake of Ga 68 dotatate reflects the level of somatostatin receptor density in NETs. Netspot is supplied as a sterile, single-dose kit for preparation of Ga 68 dotatate injection for intravenous use. This information is important for planning the appropriate course of therapy.” “Netspot provides another diagnostic tool whose results will help clinicians determine the location and extent of the tumor. 'Use of advanced imaging techniques to detect rare neuroendocrine tumors at an early stage in patients is critical,' said Libero Marzella, M.D., Ph.D., director of the Division of Medical Imaging Products in the FDA’s Center for Drug Evaluation and Research.

Ga 68 dotatate, a positron emitting analogue of somatostatin, works by binding to such receptors. NETs have receptors for somatostatin, a hormone that regulates the endocrine system. These cells are found throughout the body in organs, such as the stomach, intestines, pancreas, lungs and other locations. NETs are rare noncancerous (benign) or cancerous (malignant) tumors that develop in the hormone-producing cells of the body’s neuroendocrine system. This radioactive probe will help locate tumors in adult and pediatric patients with the rare condition, somatostatin receptor positive neuroendocrine tumors (NETs). Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging.

Netspot neuroendocrine tumor santa fe